PipelineReview.com4h
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades ...
PipelineReview.com4h
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral ...
PipelineReview.com1d
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
CAMBRIDGE, MA, USA I6, 2024 I Biogen Inc. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an ...
PipelineReview.com2d
Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor
MORRISVILLE, NC, USA I5, 2024 I Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule precision therapeutics to ...
PipelineReview.com2d
Traverse Biotech to Present Data on ROR2-Targeted T-Cell Engager at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
NEW YORK, NY, USA I5, 2024 I Traverse Biotech, Inc., a privately held biotechnology company specializing in innovative immunotherapy solutions, today announced that it will present a poster at the ...
PipelineReview.com2d
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
GAITHERSBURG, MD, USA I5, 2024 I LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical ...
PipelineReview.com2d
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
VANCOUVER, Canada I5, 2024 I Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, ...
PipelineReview.com3d
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
SOUTH SAN FRANCISCO, CA, USA I4, 2024 I Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced today that it has entered into a definitive agreement to ...
PipelineReview.com9d
Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
– The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME ...
PipelineReview.com3d
BPGbio to Present Novel E2-based Targeted Protein Degradation Program at TPD and Induced Proximity Summit
BOSTON, MA, USA I October 24, 2024 I BPGbio, Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein ...
PipelineReview.com3d
Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor
Enables ATX-559 Phase 1 study in solid tumor patients with a focus on BRCA1/2-deficient breast cancer and solid tumors with microsatellite instability (MSI-H) ...
PipelineReview.com3d
Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases
WATERTOWN, MA, USA I4, 2024 I Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene ...